Close menu




November 17th, 2022 | 10:40 CET

Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?

  • Space
  • Biotechnology
Photo credits: pixabay.com

Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , NEL ASA NK-_20 | NO0010081235 , KLEOS SPACE CDI/1/1 | AU0000015588

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Kleos Space: Will the stock still take off in 2022?

    While BioNTech and Nel have already moved well away from the low for the year, Kleos Space is still waiting for the countermovement. But this could be imminent. A SpaceX rocket is to be launched this year. On board: The fourth satellite cluster from Kleos Space. The cluster has passed all tests and is on its way to Elon Musk's SpaceX. Full commissioning will then take place by mid-2023. Three satellite clusters are already in space and are expected to be in formation this month. Accordingly, Kleos Space can start generating revenue. As a result, the shares of the specialist for space-based high-frequency reconnaissance could soon take off. The Company hopes to receive orders from the US government in the future. Initial test projects are already underway. According to analysts, Kleos Space should multiply its sales in the coming years.

    Analysts at First Berlin expect Kleos to increase sales from EUR 2.20 million in the current year to EUR 12.50 in the coming year. In 2024, this figure should then already be EUR 20.20 million. Then, a net profit of at least EUR 2 million should be achieved for the first time. With a current market capitalization of AUD 40 million, the price/earnings ratio for 2024 is just over 13. Not too much for a company in an industry of the future. Therefore, First Berlin recommends Kleos shares as a buy with a price target of AUD 1.60 (to the full report more-ir.de/d/25391.pdf).

    Nel: Bringing GM on board

    Nel's stock is still a few years away from a price-to-earnings ratio. Operating performance has disappointed this year. Nevertheless, Jefferies analysts consider the Norwegian company's stock the "Top Pick" in the hydrogen sector. They say the current order backlog makes it easy to plan for sales development until mid-2024. They, therefore, recommend Nel shares as a buy with a target price of NOK 19. But this is not the only thing Nel shareholders can be happy about. The Company is also making progress strategically. For example, the Norwegians announced a cooperation with General Motors (GM) yesterday. By combining GM's fuel cell expertise with Nel's hydrogen know-how, the partners aim to significantly reduce green hydrogen production costs.

    By combining GM's extensive fuel cell expertise and Nel's decades of knowledge in electrolyzers, the two companies aim to develop more competitive sources of renewable hydrogen. "General Motors is one of the world leaders in hydrogen fuel cell propulsion with more than 50 years of experience," said Nel CEO Håkon Volldal. "We believe this collaboration will give us a competitive advantage in industrializing the production of our PEM electrolyzers and further improving the efficiency of our technology." GM management also has high hopes for the partnership. For example, GM's fuel cell expertise is expected to help Nel scale. GM would receive payments for development work and the transfer of intellectual property. In addition, royalty payments are planned after successful product development, he said.

    BioNTech: Expand into Asia

    The BioNTech share has also performed well in recent weeks, with the share now trading at EUR 160 again. UBS believes that the share price potential has been exhausted for the time being. Although BioNTech published strong figures for the third quarter, sales and profits in the coming year are difficult to plan. Therefore, the analysts rate the shares of the Mainz-based company as "neutral" with a price target of USD 168.

    Operationally, meanwhile, BioNTech continues to go full throttle. The Mainz-based company has purchased a GMP-certified production facility in Singapore from pharmaceutical giant Novartis. The fully integrated mRNA production facility is expected to be operational by the end of 2023. In addition to mRNA for vaccines, it will also be able to produce oncology therapies in ready-to-fill batches. "The acquisition will allow us to accelerate the build-out of a state-of-the-art mRNA manufacturing facility, providing faster capacity for potential clinical trials and commercial delivery of our mRNA vaccines and therapeutics in the region. Over the coming months, we will work closely with all parties involved to ensure a smooth handover of the facility and prepare for the start of production," said Sierk Poetting, chief operating officer of BioNTech. The new manufacturing facility will also serve as the regional headquarters.


    Kleos Space's stock could take off this year. BioNTech has numerous trial results coming up in the next year. Nel needs to continue to grow into its high valuation.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read